Nuformix

Nuformix has today received the results from pre-clinical studies for its NX006 product range.

NX006 is a leading treatment in pain management with annual sales exceeding £340m in 2009. However, patients treated using the currently marketed form require a high daily dosage of over 3000 mg of this very low solubility API.

In-vivo testing of the new solid forms of NX006 created by Nuformix demonstrate an increase of up to 220% in bioavailability. Across the range of forms studied, the results conclusively demonstrate that dramatic reductions in patient dosage are achievable, as are improved release profiles and more cost-effective manufacturing.

These options are made possible by Nuformix simply via re-engineering of the solid form and were expected following significant physical property changes when compared to the parent compound.

Nuformix have therefore completed critical steps in its strategy to discover, scale-up and validate vastly improved forms of currently marketed drug products and is currently seeking collaborative partnerships to enable market approval of this product.

Nuformix has today filed another significant provisional patent application covering numerous novel solid forms of NX007, a leading cardiovascular drug.

With current annual sales growing to over £240m in 2009, NX007 is currently in late stage clinical trials for numerous new indications. The novel solid forms of NX007, re-engineered by Nuformix, offer greatly increased bioavailability for this very poorly water soluble drug.

The existing year-on-year sales growth of NX007 and high likelihood of approval for important new indications combine to make this filing a critical step forward for Nuformix in delivering against it’s strategy. As with NX006, the NX007 patent application was conceived together with Jeffrey A. Lindeman at the firm J. A. Lindeman LLC.

Nuformix has today filed a provisional patent application covering numerous novel solid forms of its NX006 product.

NX006 is a leading muscle relaxant with annual sales exceeding £340m in 2009. The novel solid forms of NX006, re-engineered by Nuformix, offer new options in terms of achieving increased bioavailability of this highly insoluble drug.

The patent application was conceived together with Jeffrey A. Lindeman who is an esteemed Intellectual Property consultant and world renowned thought leader in the field of legal issues relating to pharmaceutical solid form at the firm J. A. Lindeman LLC.